Pharmacological Manipulation of Intrahepatic Arterial Blood Flow in HCC
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02472249|
Recruitment Status : Recruiting
First Posted : June 15, 2015
Last Update Posted : May 31, 2019
|Condition or disease||Intervention/treatment||Phase|
|Hepatocellular Carcinoma||Radiation: CT perfusion Drug: Norepinephrine intra-arteriel/hepatic||Phase 4|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||15 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Hepatic Arterial Blood Flow Modulation in Patients With Hepatocellular Carcinoma: Influence of Intra-arterial Norepinephrine Assessed With CT Perfusion|
|Study Start Date :||January 2016|
|Estimated Primary Completion Date :||December 2019|
|Estimated Study Completion Date :||December 2019|
Experimental: Norepinephrine intra-arteriel/hepatic
This is the only arm of this study. These patients will receive 24 micrograms of norepinephrine in the hepatic artery with subsequent CT perfusion imaging to evaluate liver blood flow.
Radiation: CT perfusion
Two dynamic CT perfusion acquisitions of the whole liver will be performed with a 320-detectors CT, prior and after to the norepinephrine injection.
Drug: Norepinephrine intra-arteriel/hepatic
A small dose (24 ug) of norepinephrine will be injected in the hepatic artery over 10 seconds. The half-life of the drug is 90 seconds.
- Liver blood flow [ Time Frame: 1 minute following injection ]Liver blood flow as measured with CT perfusion
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02472249
|Contact: Maxime Noel-Lamy, MD FRCPC||416-946-4501 ext firstname.lastname@example.org|
|Toronto General Hospital||Recruiting|
|Toronto, Ontario, Canada, M5G 2N2|
|Contact: Maxime Noel-Lamy, MD FRCPC 416-946-4501 ext 5054 email@example.com|
|Principal Investigator:||Dheeraj Rajan, MD FRCPC||University Health Network/Mount Sinai Hospital|